MétaCan
ENFR
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

Export CSVExport JSONAPI query

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
The Lancet Oncology
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

832 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
832 works in the cohort · of 4,299,418page 4 of 17

Labels cover 9 of 832 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 832 of 832 works in this cohort. Predictions are machine_predicted_unvalidated teacher distillation outputs. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study
Éric Pujade-Lauraine, Keiichi Fujiwara, Jonathan A. Ledermann, Amit M. Oza, Rebecca Kristeleit, Isabelle-Laure Ray-Coquard +15 more
2021· article· en· The Lancet Oncology· Medicine
distilled prediction:candidate · metaepi_narrow+insufficient_payloadconsensus · none
405
citations
afffundno abstractunlabeled
Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial
Irwin Walker, Tony Panzarella, Stephen Couban, Félix Couture, Gerald M. Devins, Mohamed Elemary +12 more
2015· article· en· The Lancet Oncology· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
363
citations
affno abstractunlabeled
Cancer in sub-Saharan Africa: a Lancet Oncology Commission
Wilfred Ngwa, Beatrice Wiafe Addai, Isaac F. Adewole, Victoria Ainsworth, James Alaro, Olusegun Isaac Alatise +47 more
2022· review· en· The Lancet Oncology· Medicine
distilled prediction:candidate · metaepi_narrow+research_integrity+insufficient_payloadconsensus · none
361
citations
affno abstractunlabeled
Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial
Daniel V.T. Catenacci, Niall C. Tebbutt, Ірина Давиденко, André M. Murad, Salah‐Eddin Al‐Batran, David H. Ilson +15 more
2017· article· en· The Lancet Oncology· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
343
citations
← previousnext →

How this was built: Screen · Findings · About